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Spatial-temporal analysis of HIV-1 PR and RT resistance-associated
mutations of nucleotide sequences from Western Europe, using
vircoTYPE
TM HIV-1 assay
Van den Eede, P; Govaert, M; Soom Van, K; Villacian, J and Pattery, T
Janssen Diagnostics BVBA, Beerse, Belgium.
Highly effective regimens have drastically improved HIV morbidity and mortality although anti-retro viral resistance remains a
limiting factor in disease management. Therefore, analysis of large sequence datasets may provide better insight into drug
resistance & assist policy makers to select optimized treatment strategies. Using a secure, web-based sequence submission tool
(vircoNETTM, Janssen Diagnostics BVBA), centers within EU have been able to retrieve the CE-marked vircoTYPETM HIV-1 (VTY)
genotyping reports for their patients.The purpose of this study is to perform a descriptive analysis of the prevalence of HIV-1 PR
& RT resistance-associated mutations (RAMs) from submitted nucleotide sequences, collected during an 8 year period, from 5
West-European countries & Switzerland. From January 2005-June 2012, 27,262 sequences were submitted via vircoNETTM &
analyzed using VTY. Approximately 50% of the sequences were submitted from Spain (n14120) & 24% from Italy (n6415).
The remaining sequences were from UK (n2097), France (n1508), Germany (n1041) & Switzerland (n2081). The
majority (80%, 21,647/27,262) of the sequences were Clade B. For NRTI RAMs, M184V was the most prevalent mutation (36%,
n9944) followed by M41L (25%, n6701). For NNRTI RAMs, K103N mutation was most prevalent (24%, n6481) followed
by Y181C (10% n2704). For PIs, L90M (16%, n4453) and M46I (12%, n3397) were the most prevalent. The overall RAM
prevalence has declined over the 8 year period. 7602 (28%) sequences had no major RAMs and were sensitive to all 18 FDA
& EMA-approved drugs present on VTY. In the PI class, VTY predicted 95% (20097/21243) of the sequences as sensitive & 5%
(1146/21243) resistant to darunavir, followed by tipranavir, lopinavir & saquinavir with equal sensitivity rate (SR) of 81% &
a resistance rate (RR) of 13%, 18% & 19% respectively. In the NNRTI class, etravirine had a better SR (81%, 8628/10683) & RR
(19%, 2055/10683) when compared to nevirapine and efavirenz, with a SR of 59% & RR of 41% for both drugs. For NRTIs, the
highest SR was found for stavudine (77%, 20889/27262) followed by tenofovir (67%, 18249/27262) with 23% (6499/27262)
resistant sequences observed for stavudine & 33% (9114/27262) for tenofovir. The current analysis provides some preliminary
insight into HIV mutation pattern prevalence and resistance within Western Europe, suggesting good therapeutic opportunities
for regimens containing new generation PIs & NNRTIs.
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